Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50
Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50
高盛以買入評級啓動對Immunovant的報道,宣佈目標股價爲50美元
Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $50.
高盛分析師科琳娜·約翰遜開始對Immunovant(納斯達克股票代碼:IMVT)進行報道,評級爲買入,並宣佈目標股價爲50美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。